Autopsy report · NCT07084831

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

“Ethical committee in Europe did not provide approval”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

European Group for Research In Schizophrenia

Sponsor type

University, hospital or other

Conditions

Schizophrenia; Psychosis; Cognitive Impairment

Interventions

Xanomeline/trospium

Participants

0

Sites

16

Countries

Austria, Belgium, Czechia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Spain

Trials that died the same way

• Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
  “No approval from ethical committee” (82% match in meaning)
• Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
  “Not approved by the coordinating Ethical Committee” (74% match in meaning)
• Identification of Post-Traumatic Stress Disorder in Adult Patients With Substance Use Disorders
  “Refusal by the Ethics Committee” (66% match in meaning)
• Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia
  “The necessary ethical approvals were not obtained in a timely manner.” (65% match in meaning)
• The Effect of ACT and Float REST on Burnout Syndrome.
  “Ethics Committee concerns.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.